Pharmarise Holdings (2796) · RiskRestated
Gap Between Provisional Procurement Prices and Agreed Prices After Drug Price Revisions
First written in FY2017. 3 of 4 entries say "Restated". Latest entry: FY2021.
4entries
5years
0from disclosures
How it moved
Same theme, other companies
Gap Between Provisional Procurement Prices and Agreed Prices After Drug Price RevisionsA theme 2 companies write about · 2 as a headwind · 0 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2021RestatedAnnual report
「If a significant difference arises between the provisional price and the agreed price in the future, it could affect the Group's results.」
The risk of a difference between provisional procurement prices and agreed prices after a drug price revision continues. - FY2020RestatedAnnual report
「If a significant difference arises between the provisional price and the agreed price in the future, it could affect the Group's results.」
The risk of a difference between provisional procurement prices and agreed prices after a drug price revision continues. - FY2018RestatedAnnual report
「If a significant difference arises between the provisional price and the agreed price in the future, it could affect the Group's results.」
The risk of a difference between provisional procurement prices and agreed prices after a drug price revision continues. - FY2017First statedAnnual report
「If a significant difference arises between the provisional price and the agreed price in the future, it could affect the Group's results.」
The price difference risk associated with the practice of recording provisional prices after a drug price revision until final procurement prices are agreed with pharmaceutical wholesalers was disclosed.